Bifogade filer
PR EN FRACTAL ESC 2024 240718
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Kancera AB (publ) announces that the results from the FRACTAL study will be presented at the European Society of Cardiology (ESC) annual conference on September 2, 2024.
In December 2023, Kancera reported positive top-line results from the FRACTAL study, an exploratory phase IIa study of Kancera’s candidate drug KAND567 in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention.
The results from the FRACTAL study will now be presented at the ESC Conference 2024 on September 2, by Professor Ioakim Spyridopoulos, primary investigator in the FRACTAL study. ESC is the world's largest conference in cardiovascular medicine where the world's leading cardiology experts convene to advance the field through ground-breaking research and pioneering technologies.
About the FRACTAL study
The FRACTAL study is an explorative clinical phase IIa study of KAND567 when added to standard of care in ST-elevation myocardial infarction (STEMI) patients undergoing acute primary percutaneous coronary intervention (PCI), including heparin, glycoprotein IIb/IIIa inhibitors and dual antiplatelet inhibitors. The study, a two-arm, double-blinded and placebo-controlled study, was conducted at the two hospitals: the Freeman Hospital in Newcastle and the James Cook University Hospital in Middlesbrough. Primary investigator of the study was Professor Ioakim Spyridopoulos, Professor of Cardiology and Cardiovascular Gerontology, Newcastle University.
Participants were randomized (1:1) to receive intravenous infusion of KAND567 for 6 hours, followed by a bridging dose of up to 200mg KAND567 orally after the infusion (bridging dose dependent on the time of primary PCI procedure, followed by 8 doses of 200mg of KAND567, 8 hours apart, or a matched placebo).
All participants who received any dose of KAND567 or placebo, and for whom any post-dose data were available were included in the safety analysis set. Any participant receiving any dose of KAND567 was treated as if they were allocated to the active arm. Of the 71 patients recruited in total, 37 and 34 patients were randomized to the KAND567 group and placebo group, respectively.
The primary objective was to evaluate safety and tolerability of KAND567, assessed on Adverse Events, Severe Adverse Events and Suspected Unexpected Serious Adverse Reactions, cumulatively for each arm from baseline up to day 90 and on safety laboratory parameters. The secondary objective was to evaluate signs of cardio-protective effects, which has been assessed through a range of inflammatory biomarkers and magnetic resonance imaging (MRI) markers.
About Kancera AB (publ)
Kancera is developing a new class of small molecule drugs targeting the fractalkine axis. Kancera’s main focus is to develop its candidate drugs for treatment of severe inflammatory diseases and cancer that currently lack effective treatments. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.
For further information
- Presentations of the FRACTAL study results are available on Kancera’s website: www.kancera.com/en/investor-relations/presentations/
- The agenda for the ESC 2024 Conference is available on ESC’s website: https://esc365.escardio.org/ESC-Congress/schedule
or contact:
ir@kancera.com or +46 (0)8-5012 60 80